Symbiosis Pharmaceutical Services
Stirling, UK
Program data pending ClinicalTrials.gov matching
· Last scored 2026-03-15
56.5
Signal Score
✓ FDA Inspections (1)
○ Clinical Trials
○ SEC Filings
✓ Press (3)
Quick Facts: Symbiosis Pharmaceutical Services
- Signal Score
- 56.5/100 (as of 2026-03-15)
- Quality Compliance
- Assessment pending
- Headquarters
- Stirling, UK
- Modalities
- Cell Therapy
- Active CGT Programs
- No ClinicalTrials.gov matches confirmed
- Data Sources
- FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
- Scored By
- CDMO Signal — independent CGT manufacturing intelligence platform
Signal Score & Pillar Breakdown
Quality Compliance
—
No FDA inspection records found. This CDMO may operate under a different legal name or may not have US FDA-inspected facilities.
FDA Inspections1 on record
Warning Letters0
Last InspectionNo Action Indicated (NAI) (2025-01-31)
Operations
—
No ClinicalTrials.gov facility matches confirmed for this manufacturer.
Programs
— no verified data
Sponsors— no verified data
ModalitiesCell Therapy
No clinical trial matches found for this manufacturer
Operational score requires ClinicalTrials.gov data
Data sourced from ClinicalTrials.gov, FDA, SEC EDGAR, and verified press only. No unverified estimates shown.
Financial Stability
60.0
Private company
Financial assessment: 60.0/100
Source: SEC EDGAR, press monitoring
Profile-based financial assessment
SEC FilingsPrivate company
Private company
Financial assessment: 60.0/100
Capacity
53.0
1 CGT manufacturing site: Stirling, UK
Modalities: Cell Therapy
Capacity assessment: 53.0/100
Sites: Stirling, UK
Source: SEC EDGAR, press monitoring, company profiles
1 CGT manufacturing site
Recent Press3 articles
1 CGT manufacturing site: Stirling, UK
Modalities: Cell Therapy
Capacity assessment: 53.0/100
FDA Inspection History
2025-01
NAI
VAI
OAI
| Date | Site | Type | Observations | Classification |
|---|---|---|---|---|
| 2025-01-31 | Stirling | Human Cellular, Tissue, and Gene Therapies | No | No Action Indicated (NAI) |
Source: FDA Data Dashboard · Retrieved Mar 20, 2026
Recent News 3 articles
Symbiosis Appoints Joanne Anderson as Chief Commercial Officer - CHEManager
Symbiosis Appoints Joanne Anderson as Chief Commercial Officer CHEManager
Symbiosis appoints Joanne Anderson as Chief Commercial Officer - Pharmafile
Symbiosis appoints Joanne Anderson as Chief Commercial Officer Pharmafile
Symbiosis Appoints Joanne Anderson as Chief Commercial Officer - Contract Pharma
Symbiosis Appoints Joanne Anderson as Chief Commercial Officer Contract Pharma
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in: